Approaches for the development of drugs for treatment of obesity and metabolic syndrome

dc.creatorMaksimov M.L.
dc.creatorSvistunov A.A.
dc.creatorTarasov V.V.
dc.creatorChubarev V.N.
dc.creatorÁvila-Rodriguez M.
dc.creatorBarreto G.E.
dc.creatorDralova O.V.
dc.creatorAliev G.
dc.date.accessioned2020-09-02T22:21:58Z
dc.date.accessioned2022-11-08T20:20:36Z
dc.date.available2020-09-02T22:21:58Z
dc.date.available2022-11-08T20:20:36Z
dc.date.created2020-09-02T22:21:58Z
dc.date.issued2016
dc.identifier22, 7, 895-903
dc.identifier13816128
dc.identifierhttps://hdl.handle.net/20.500.12728/5163
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/5143657
dc.languageen
dc.publisherBentham Science Publishers
dc.subjectAdipokines
dc.subjectBeloranib
dc.subjectContrave®
dc.subjectEmpatic™
dc.subjectLiraglutide
dc.subjectLorcaserin
dc.subjectOrlistat
dc.subjectPharmacotherapy of obesity
dc.subjectQsymia
dc.subjectRimonabant
dc.subjectSibutramine
dc.subjectTesofensine
dc.subjectTreatment of obesity and ms
dc.subjectagents affecting metabolism
dc.subjectamfebutamone
dc.subjectamfebutamone plus naltrexone
dc.subjectamfebutamone plus zonisamide
dc.subjectantiobesity agent
dc.subjectbeloranib
dc.subjectexendin 4
dc.subjectfluoxetine
dc.subjectliraglutide
dc.subjectlorcaserin
dc.subjectmetformin plus sitagliptin
dc.subjectmetreleptin
dc.subjectnaltrexone
dc.subjectnoradrenalin
dc.subjectpancreas enzyme
dc.subjectphentermine plus topiramate
dc.subjectrimonabant
dc.subjectserotonin
dc.subjectsibutramine
dc.subjecttesofensine
dc.subjecttetrahydrolipstatin
dc.subjecttopiramate
dc.subjectvenlafaxine
dc.subjectantiobesity agent
dc.subjectArticle
dc.subjectbehavior therapy
dc.subjectbody weight
dc.subjectcardiovascular system
dc.subjectdrug design
dc.subjectdrug efficacy
dc.subjectdrug safety
dc.subjectenergy metabolism
dc.subjecthuman
dc.subjectlife expectancy
dc.subjectlipid absorption
dc.subjectmedical practice
dc.subjectmetabolic syndrome X
dc.subjectmorbid obesity
dc.subjectobesity
dc.subjectphysical activity
dc.subjectpriority journal
dc.subjectsleep disordered breathing
dc.subjectstomach secretion
dc.subjectweight reduction
dc.subjectanimal
dc.subjectbody mass
dc.subjectcomplication
dc.subjectdrug design
dc.subjectdrug potentiation
dc.subjectmetabolic syndrome X
dc.subjectobesity
dc.subjectpathophysiology
dc.subjectrisk factor
dc.subjectAnimals
dc.subjectAnti-Obesity Agents
dc.subjectBody Mass Index
dc.subjectDrug Design
dc.subjectDrug Synergism
dc.subjectHumans
dc.subjectMetabolic Syndrome X
dc.subjectObesity
dc.subjectRisk Factors
dc.titleApproaches for the development of drugs for treatment of obesity and metabolic syndrome
dc.typeArticle


Este ítem pertenece a la siguiente institución